● Recruiting

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

Condition: Non-hodgkin Lymphoma,B Cell · Sponsor: Bioray Laboratories

PhasePhase 1

Planned participants18

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a multi-center, single-arm, open-label clinical study, and the sample size is set to 12-18 subjects.

This description comes directly from the study's public registry record.

Talk to the study team

Wei Li, PhD · 18621670308 · wli@brlmed.com

Always discuss trial participation with your own doctor first.

Locations (3)

Wuhan Union Hospital	Wuhan, Hubei, China	Recruiting
Tianjin Institute of Hematology	Tianjin, Tianjin Municipality, China	Recruiting
The First Affiliated Hospital of Zhejiang University	Hangzhou, Zhejiang, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05741359